MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Search

Ligand Pharmaceuticals Inc

Abierto

SectorSanidad

197.55 0.12

Resumen

Variación precio

24h

Actual

Mínimo

194.95

Máximo

202.13

Métricas clave

By Trading Economics

Ingresos

112M

117M

Ventas

115M

P/B

Media del Sector

84.636

89.037

Margen de beneficios

101.569

Empleados

68

EBITDA

87M

149M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+22.05% upside

Dividendos

By Dow Jones

Próximas Ganancias

26 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-321M

3.8B

Apertura anterior

197.43

Cierre anterior

197.55

Noticias sobre sentimiento de mercado

By Acuity

23%

77%

55 / 360 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Ligand Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 ene 2026, 23:49 UTC

Principales Movimientos del Mercado

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21 ene 2026, 21:12 UTC

Principales Movimientos del Mercado

Automaker Stocks Rise After Trump Calls Off European Tariffs

21 ene 2026, 21:00 UTC

Adquisiciones, fusiones, absorciones

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21 ene 2026, 20:29 UTC

Principales Movimientos del Mercado

Chip Makers Gain After Trump Calls Off European Tariffs

21 ene 2026, 20:04 UTC

Principales Movimientos del Mercado

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21 ene 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21 ene 2026, 23:34 UTC

Charlas de Mercado

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21 ene 2026, 22:39 UTC

Ganancias

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21 ene 2026, 21:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

21 ene 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

21 ene 2026, 21:35 UTC

Adquisiciones, fusiones, absorciones

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21 ene 2026, 21:19 UTC

Ganancias

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21 ene 2026, 20:45 UTC

Adquisiciones, fusiones, absorciones

Deutsche Borse Group to Acquire Allfunds for $6.19B

21 ene 2026, 20:36 UTC

Charlas de Mercado

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21 ene 2026, 20:31 UTC

Charlas de Mercado

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21 ene 2026, 20:27 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21 ene 2026, 20:27 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

21 ene 2026, 20:27 UTC

Charlas de Mercado

Was It a 'TACO' Event? -- Market Talk

21 ene 2026, 20:26 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21 ene 2026, 20:23 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21 ene 2026, 20:21 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21 ene 2026, 20:19 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse Group Agrees to Buy Allfunds

21 ene 2026, 20:08 UTC

Ganancias

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21 ene 2026, 20:03 UTC

Charlas de Mercado

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21 ene 2026, 19:51 UTC

Charlas de Mercado

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21 ene 2026, 19:43 UTC

Charlas de Mercado

U.S. Ethanol Production Expected to Slip -- Market Talk

21 ene 2026, 19:31 UTC

Charlas de Mercado

Gold Settles at Fresh All-Time High -- Market Talk

21 ene 2026, 19:24 UTC

Ganancias

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21 ene 2026, 19:10 UTC

Charlas de Mercado

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21 ene 2026, 18:57 UTC

Charlas de Mercado

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Comparación entre iguales

Cambio de precio

Ligand Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

22.05% repunte

Estimación a 12 Meses

Media 243.5 USD  22.05%

Máximo 275 USD

Mínimo 220 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ligand Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

7

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

102.5 / 109.24Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Weak Bullish Evidence

Sentimiento

By Acuity

55 / 360 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
help-icon Live chat